Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced a national contract with Novation for ABLAVAR® (gadofosveset trisodium) and DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, providing increased access to these important diagnostic imaging agents for health care providers served by Novation. Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two health care alliances, and 5,500 members of Provista, LLC, representing 28,000 sites.
"We are pleased to announce this agreement with one of the nation's largest group purchasing organizations for the distribution of ABLAVAR® and DEFINITY®," said Robert Spurr, Vice President, Sales and Marketing at Lantheus Medical Imaging. "Novation can now offer the members they serve access to the clinical benefits of these valuable contrast imaging agents. ABLAVAR® is a novel magnetic resonance angiography (MRA) blood pool imaging agent indicated for evaluation of aortoiliac disease (AIOD) in adults with known or suspected peripheral vascular disease, while DEFINITY® is used in patients with suboptimal echocardiograms to opacify the left ventrical chamber and to improve the delineation of the left ventricular endocardial border."
Diagnostic imaging agents like ABLAVAR® and DEFINITY® can help physicians in the diagnosis and treatment of disease. These agents are used to improve image quality. ABLAVAR® makes it possible for physicians to detect vascular disease using MRA, which is less invasive than conventional X-ray angiography, the current standard of care, and without exposing patients to ionizing radiation. DEFINITY® is used to improve image quality in patients with suboptimal echocardiograms.